Jesper Lagergren

Jesper Lagergren

Professor/Senior Physician
Visiting address: Blombäcks väg 23, plan 4, 17177 Stockholm
Postal address: K1 Molekylär medicin och kirurgi, K1 MMK Övre GI-kirurgi, 171 77 Stockholm
Part of:

About me

  • Academic surgeon focusing on oesophageal and gastric cancer and conditions associated with these tumours, including gastro-oesophageal reflux disease, Barrett's oesophagus, obesity, peptic ulcer and Helicobacter pylori-infection.

    Holder of two tenured combined professorships and senior consultant surgeon positions, one full-time at Karolinska Institutet and Karolinska University Hospital, and one part-time at King's College London and Guy's and St. Thomas' NHS Foundation Trust in London.

    Member of the Nobel Assembly at KI.
    Chair of the Recruitment Committee at KI.

Research

  • Leader of the research group Upper Gastrointestinal Surgery at the Department of Molecular medicine and Surgery.

    CV: MD in 1989, specialist surgeon in 1996, doctorate (PhD) in 1999, consultant surgeon in 2000, docent in surgery in 2001, associate professor of surgery in 2003, and professor of surgery since 2006, all at Karolinska Institutet, and professor and consultant surgeon at King's College London and Guy's and St. Thomas' NHS Foundation Trust in London since 2010.

    Supervision: Supervised 45 doctorate students to completed PhDs (24 as main supervisor). Presently main supervisor of another 8 PhD students. Previous supervisor of 20 post-doctoral researchers, and presently another 2.

    Publications: Over 450 peer reviewed scientific articles, with the majority (62%) as last or first author.

Teaching

  • Docent in 2001 and full professor since 2006. Currently mainly supervision of PhD students and post-docs, but also some supervision of master students and medical students. Teacher at PhD courses. Organiser of seminars, workshops and conferences. Invited speaker or chair at international conferences.

Selected publications

Articles

All other publications

Grants

  • National Institute for Health and Care Research
    1 July 2023 - 30 June 2028
    QUESTION: Does the LINX procedure achieve similar reflux control and improve postoperative symptoms, specifically gas bloating and inability to belch, when compared to laparoscopic fundoplication? BACKGROUND: Gastro-oesophageal reflux disease (GORD) represents a significant burden on the Western healthcare system, affecting up to 20% of adults. Laparoscopic fundoplication is currently the gold standard surgical treatment for managing GORD, the late complications include gas bloating, dysphagia, and recurrence of reflux. The LINX procedure involves laparoscopic placement of the LINX device around the distal oesophagus and comprises titanium beads with magnets in the centre that augment lower oesophageal tone and thus prevent reflux. AIMS: This study aims to determine whether the LINX procedure achieves similar reflux control and improves postoperative symptoms, specifically gas bloating and inability to belch, when compared to fundoplication at 24 months after surgery. Secondary aims are to compare the prevalence and severity of reflux, gas bloating and inability to belch at 6 weeks, 6, and 12 months, regurgitation, dysphagia, global health-related quality of life (HRQL) and utilisation of anti-GORD medications at 6 weeks, 6, 12 and 24 months, objective assessment of lower oesophageal acid exposure using 24hr pH manometry or BRAVO test at 12 months and 30-day, 90-day, 12 and 24-month complication rates. The mechanistic research will aim to provide a unique understanding of technical surgical factors that underpin patient reported outcome measures (PROMS) after anti-reflux surgery, through detailed video analysis with robust surgical quality assurance (SQA). METHODS: A prospective, multi-centre, pragmatic, double-blind phase III RCT design will be utilised, randomising patients 1:1 between laparoscopic LINX procedure and fundoplication. The setting will be at least 16 UK and 4 European large upper gastro-intestinal surgical centres. With the support of an integrated QuinteT Recruitment Intervention (QRI) to optimise recruitment, we will recruit 460 patients recommended for anti-reflux surgery with GORD. Patients will be randomised 1:1 to receive either laparoscopic LINX procedure or fundoplication. The primary outcome is assessment of symptomatic GORD and HRQL using the GORD-HRQL questionnaire at 24 months following surgery, and key secondary outcomes are prevalence of inability to belch and gas bloating at 24 months. Patients will be followed-up at baseline, 6 weeks, 6, 12 and 24 months. All procedures will be recorded, and videos will be annotated, these will then be compared with data relating to post-operative complications and PROMS. TIMELINES The total length of the trial is 60 months. Recruitment will last 24 months and there will be a formal stop/go review of the internal pilot in month 14 of the project (8th month of recruitment) to ensure that a minimum of 15 centres are active and recruiting at least 1-3 patients/centre/month. Data from the patients in the internal pilot phase will be included in the final analysis. IMPACT We anticipate that the study results will change national guidelines for GORD and thus affect over 2000 patients who are treated with surgery in the UK annually. The findings are likely to extend beyond the UK and dissemination will be through publications, presentations, and appropriate use of media. We have incorporated a full patient and public involvement programme.<br/>Gastro-oesophageal reflux disease (GORD) is a common condition in which acid from the stomach passes back (reflux) into the gullet (oesophagus). It typically occurs due to weakening of the ring of muscle at the bottom of the oesophagus (the lower oesophageal sphincter). GORD is more common in older people and in women, however, can affect anyone of any age or ethnicity. The most common symptoms are heartburn and an unpleasant taste in the back of the mouth. Although GORD may be only an occasional nuisance for most people, there are others in whom it has a severe impact upon their quality-of-life. It can lead to several complications, including ulceration and narrowing of the oesophagus. The most serious complication (2 in 10 people) is called Barrett's oesophagus
    a change in the lining of the oesophagus that increases the risk of developing oesophageal cancer. In most cases, GORD can be controlled with self-help measures and medication. However, there are instances in which surgery is recommended. The current best surgical treatment for GORD is called a fundoplication. This operation, which is carried out through keyhole (laparoscopic) surgery, tightens the lower oesophagus to prevent acid reflux. Fundoplication has an excellent safety profile and produces an improvement in the quality of life of many patients. However, there are a significant number of patients who suffer from gas bloating (8 out of 10 people), difficulty swallowing (2 out of 10 people) and a recurrence of their GORD symptoms (6 out of 10 people) after fundoplication. As an alternative to fundoplication, some surgeons have started to use a device called LINX, through a similar keyhole operation. LINX is a magnetic band that wraps around the lower part of the oesophagus to prevent acid reflux. Small scale studies suggest that LINX may cause fewer complications than fundoplication, albeit at the cost of a more modest improvement in quality-of-life. However, before LINX can safely overtake fundoplication as the primary means of surgically treating GORD, there is a need to generate more conclusive evidence. In order to meet this need, we have designed a multi-centre study which aims to determine whether the LINX procedure achieves similar reflux control and improves symptoms when compared to fundoplication. We intend to measure (1) quality of life, (2) complications related to the operation, including the need for additional treatment, (3) the financial cost effectiveness and (4) the presence of acid in the lower oesophagus. Given that there is no clear 'better' surgical option between the two options, 230 patients will be randomly allocated to receive either fundoplication or the insertion of the LINX device. This study will be conducted across 16 UK and 4 European large specialist surgical centres. Patients participating in the study will be followed up at regular intervals (6 weeks, 6 months, 12 months and 24 months) to better understand which treatment option offers the best results. Moreover, we will implement a quality assurance programme within participating study centres to ensure that the procedures are completed to a high-quality standard. As part of this, all procedures will be recorded and assessed. We anticipate that the study results, which will incorporate a full patient and public involvement programme, will change national and international guidelines for GORD treatment.
  • Swedish Cancer Society
    1 January 2022
    Cancer of the esophagus and stomach are among the most common and most deadly forms of cancer. They cause over 1.3 million deaths per year globally. The poor survival is mainly due to 1) lack of effective ways to prevent the appearance of these tumors, 2) late detection when the tumors have already grown large and spread via daughter tumors, and 2) lack of evidence for standardized and optimized surgical treatment. The main factors for the development of esophageal and stomach cancer are infection with the stomach bacterium Helicobacter pylori (HP), severe heartburn (reflux disease), obesity and male sex. The main treatment is surgery. The project will demonstrate how treatment of factors behind esophageal and gastric cancer changes the risk of these tumors. We will investigate how antibiotics and proton pump inhibitors for HP, surgery for reflux disease, surgery for obesity, and hormone therapy for menopause affect cancer risk. We will also clarify what number of lymph nodes should be removed during surgery for esophageal cancer and how the surgeon's and the hospital's annual number of gastric cancer surgeries affect survival. The studies are based on large Nordic or Swedish data collections with detailed information, which is needed for good statistical power and high scientific quality. The overall objective of the research project is that it should contribute to fewer people dying from esophageal or stomach cancer. This can be achieved by demonstrating measures that prevent people with an increased risk of these tumors from becoming ill or enable earlier detection of the tumors in a curable stage, which i.a. can conceivably take place via treatment of HP infection, reflux disease and obesity, as well as hormone therapy. The research should also contribute to improved surgical treatment, i.a. by demonstrating how many lymph nodes should be removed and whether centralization to fewer surgeons and hospitals improves survival after surgery.
  • The risk of oesophageal adenocarcinoma after eradication treatment of Helicobacter pylori
    Sjöbergstiftelsen
    1 January 2021
  • Cancer Research UK
    1 August 2018 - 31 July 2020
  • Nordic Cancer Union

Employments

  • Professor/Senior Physician, Department of Molecular Medicine and Surgery, Karolinska Institutet, 2006-

Degrees and Education

  • Docent, Karolinska Institutet, 2001
  • Doctor Of Philosophy, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, 1999

News from KI

Events from KI